Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial

Por Rothermundt, C, Hubner, R, Ahmad, T, Gibbens, I, Keyzor, C, Habeshaw, T, Kaye, S, Gore, M
Publicado em 2006

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma

Por Larkin, J M G, Hughes, S A, Beirne, D A, Patel, P M, Gibbens, I M, Bate, S C, Thomas, K, Eisen, T G, Gore, M E
Publicado em 2007

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

Por Harries, M, Moss, C, Perren, T, Gore, M, Hall, G, Everard, M, A'Hern, R, Gibbens, I, Jenkins, A, Shah, R, Cole, C, Pizzada, O, Kaye, S
Publicado em 2004

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Por Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Publicado em 2006

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

Por Eisen, T, Marais, R, Affolter, A, Lorigan, P, Robert, C, Corrie, P, Ottensmeier, C, Chevreau, C, Chao, D, Nathan, P D, Jouary, T, Harries, M, Negrier, S, Montegriffo, E, Ahmad, T, Gibbens, I, James, M G, Strauss, U P, Prendergast, S, Gore, M E
Publicado em 2011